Chimerix Inc’s recently made public that its CHIEF MEDICAL OFFICER Melemed Allen S. unloaded Company’s shares for reported $13799.0 on Feb 13 ’25. In the deal valued at $4.50 per share,3,065 shares were sold. As a result of this transaction, Melemed Allen S. now holds 152,875 shares worth roughly $0.71 million.
Then, Andriole Michael T. sold 7,370 shares, generating $33,282 in total proceeds. Upon selling the shares at $4.52, the PRESIDENT AND CEO now owns 609,603 shares.
Before that, Alrutz Michael Albert sold 1,600 shares. Chimerix Inc shares valued at $7,226 were divested by the SVP AND GENERAL COUNSEL at a price of $4.52 per share. As a result of the transaction, Alrutz Michael Albert now holds 213,596 shares, worth roughly $1.0 million.
Robert W. Baird initiated its Chimerix Inc [CMRX] rating to an Outperform in a research note published on May 23, 2023; the price target was $7. A number of analysts have revised their coverage, including CapitalOne’s analysts, who began to cover the stock in early September with a ‘”an Overweight”‘ rating. Maxim Group began covering CMRX with “Buy” recommendation on April 29, 2021.
Price Performance Review of CMRX
On Tuesday, Chimerix Inc [NASDAQ:CMRX] saw its stock fall -1.89% to $4.67. Over the last five days, the stock has lost -3.31%. Chimerix Inc shares have risen nearly 34.20% since the year began. Nevertheless, the stocks have risen 295.76% over the past one year. While a 52-week high of $5.53 was reached on 02/19/25, a 52-week low of $0.75 was recorded on 01/13/25. SMA at 50 days reached $3.77, while 200 days put it at $1.63.
Levels Of Support And Resistance For CMRX Stock
The 24-hour chart illustrates a support level at 4.53, which if violated will result in even more drops to 4.38. On the upside, there is a resistance level at 4.82. A further resistance level may holdings at 4.96. The Relative Strength Index (RSI) on the 14-day chart is 60.40, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at 0.31, which suggests price will go down in the next trading period. Percent R suggests that price movement has been low at 51.09%. Stochastics %K at 61.07% indicates the stock is a holding.
The most recent change occurred on March 31, 2021 when Wedbush began covering the stock and recommended ‘”an Outperform”‘ rating along with a $21 price target.
